Objectives: Investigations of acute respiratory distress syndrome in adults suggest hypoxemia is an uncommon cause of death. However, the epidemiology of death in pediatric acute respiratory distress syndrome is not well characterized. We aimed to describe the cause, mode, and timing of death in pediatric acute respiratory distress syndrome nonsurvivors. We hypothesized that most deaths would be due to nonpulmonary factors, rather than hypoxemia. Design: Retrospective, decedent-only analysis. Setting: Two large, academic PICUs. Patients: Nonsurvivors with pediatric acute respiratory distress syndrome. Interventions: None. Measurements and Main Results: Of 798 subjects with pediatric acute respiratory distress syndrome, there were 153 nonsurvivors (19% mortality). Median time to death was 6 days (interquartile range, 3-13 d) after pediatric acute respiratory distress syndrome onset. Patients dying less than 7 days after pediatric acute respiratory distress syndrome onset had greater illness severity and worse oxygenation. Patients dying less than 7 days were more likely to die of a neurologic cause, including brain death. Patients dying greater than or equal to 7 days after pediatric acute respiratory distress syndrome onset were more commonly immunocompromised. Multisystem organ failure predominated in deaths greater than or equal to 7 days. Withdrawal of therapy was the most common mode of death at all timepoints, accounting for 66% of all deaths. Organ dysfunction was common at time of death, irrespective of cause of death. Refractory hypoxemia accounted for only a minority of pediatric acute respiratory distress syndrome deaths (20%). Conclusions: In pediatric acute respiratory distress syndrome, early deaths were due primarily to neurologic failure, whereas later deaths were more commonly due to multisystem organ failure. Deaths from neurologic causes accounted for a substantial portion of nonsurvivors. Refractory hypoxemia accounted for only a minority of deaths. Our study highlights limitations associated with using death as an endpoint in therapeutic pediatric acute respiratory distress syndrome trials. (Crit Care Med 2018; 46:1811-1819 
A dult acute respiratory distress syndrome (ARDS) short-term mortality remains high, up to 40% in recent observational studies (1, 2) . In pediatric ARDS (PARDS), mortality rates are half of adult rates (3) (4) (5) (6) . Studies examining the epidemiology of cause of death in adults demonstrate that refractory hypoxemia is uncommon (7, 8) and that the majority of nonsurvivors die of multisystem organ failure (MSOF) or due to poor neurologic prognosis. This has relevance because interventions that target hypoxemia, such as inhaled nitric oxide (9) , exogenous surfactant (10) , and fluidconservative therapy (11) , have not improved mortality.
Few studies have investigated the cause of death in PARDS and none with modern definitions and management (6) . The degree to which mortality may be primarily attributable to PARDS, exacerbated by PARDS, or associated with the inciting insult or comorbidities is unknown. Despite this uncertainty, all-cause mortality remains a common endpoint, either alone or as part of a composite (11) (12) (13) (14) . Understanding the epidemiology of death in modern PARDS is crucial for trial design, especially as it relates to subject eligibility and choice of endpoints.
We aimed to describe the cause, mode, and timing of death in a large, modern cohort of PARDS nonsurvivors. We hypothesized that the majority of deaths in PARDS would not be due to the underlying pulmonary injury but rather due to nonpulmonary factors. A secondary aim was to describe the prevalence of specific organ dysfunctions at the time of death.
METHODS Population
We performed a retrospective observational study on all PICU nonsurvivors with PARDS at the Children's Hospital of Philadelphia (CHOP) and the Children's Hospital of Los Angeles (CHLA). The study was approved by the respective Institutional Review Boards, and requirement for informed consent waived. The CHOP cohort is a prospectively enrolling study of invasively ventilated children meeting American-European Consensus Conference acute lung injury criteria (two consecutive Pao 2 /Fio 2 ≥ 300 separated by ≥ 1 hr with bilateral infiltrates) between July 1, 2011, and June 30, 2017. As the study was initiated prior to the Berlin definition (15) , minimum positive end-expiratory pressure (PEEP) was not specified; however, CHOP PICU does not use PEEP less than 5 cm H 2 O. Thus, all patients met Berlin criteria. Similarly, as the study was initiated prior to the Pediatric Acute Lung Injury Consensus Conference (PALICC) definition of PARDS (16), we did not screen using oxygenation index (OI); however, all patients met PARDS criteria. The CHLA cohort was obtained by retrospective screen of the electronic health record and a local database for invasively ventilated children with qualifying Pao 2 or peripheral oxygen saturation (Spo 2 ) less than or equal to 97% within the first week of ventilation between March 1, 2009, and April 30, 2013 . For patients meeting the hypoxemia screening, chart review was performed to determine whether subjects met PALICC PARDS criteria by either OI (≥ 4) or oxygen saturation index (OSI ≥ 5).
Data Collection
Medical records were independently reviewed by two investigators at each site. A data dictionary was developed prior to chart abstraction (Supplementary Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/D928). Cause of death was assigned to one of three exclusive categories: 1) persistent hypoxemia, 2) MSOF, or 3) neurologic dysfunction. Mode of death was also assigned one of three exclusive categories: 1) withdrawal or withholding of life-sustaining therapies, 2) unsuccessful cardiopulmonary resuscitation (CPR), or 3) brain death, as has been described previously in PICU nonsurvivors (17, 18) . Organ failures present at time of death were defined using Goldstein criteria for septic children (19) . Disagreements in classification of cause of death, mode of death, or presence of organ failures were resolved by consensus discussion among investigators. The primary outcome was time to death counted from days after PARDS onset, stratified into less than 7 days (early) and greater than or equal to 7 days (late) after PARDS onset. In a secondary analysis, we explored more granular timepoints, divided into less than or equal to 3 days, 4 to less than 7 days, 7-14 days, and greater than 14 days after PARDS onset.
Equations and Definitions
Oxygenation was measured using OI (mean airway pressure [mPaw] × Fio 2 × 100)/Pao 2 ) or OSI (mPaw × Fio 2 × 100)/Spo 2 ) ensuring 80% greater than Spo 2 less than or equal to 97%. The designation "immunocompromised" required presence of an immunocompromising diagnosis (oncologic, immunologic, rheumatologic, or transplant) and active chemotherapy or a congenital immunodeficiency (3, 20 
RESULTS

Cause and Mode of Death in PARDS
Of 798 subjects with PARDS, there were 153 nonsurvivors (19% mortality) ( Table 1) . Of the CHLA cohort (n = 254), 110 (43%) were diagnosed using OSI, including 26 of 60 nonsurvivors (43%). Median time to death was 6 days (IQR, 3-13 d) after PARDS onset (Fig. 1) . Patients dying earlier had higher PRISM scores (p < 0.001) and greater PARDS severity (p = 0.037). Immunocompromised subjects comprised 35% of all nonsurvivors and constituted 51% of late (≥ 7 d) deaths.
Patients dying less than 7 days after PARDS onset were more likely to die of a neurologic cause of death (p < 0.001) ( Table 1) . MSOF predominated as cause of death greater than or equal to 7 days after PARDS onset. Fourteen of 17 subjects (82%) with aspiration died of neurologic causes. Of these 17 subjects, one (6%) had chronic neurologic dysfunction and 14 (82%) had acute neurologic dysfunction coincident with PARDS onset. Withdrawal of therapy was the most common mode of death, accounting for 66% of deaths. Unsuccessful CPR and brain death were more common less than 7 days after PARDS onset, whereas withdrawal of therapy became more common as a mode of death greater than or equal to 7 days (p < 0.001). Twenty-three of 59 subjects (39%) with a neurologic cause of death underwent withdrawal; the remaining 36 (61%) were brain dead. Withdrawal also occurred in 87% of those dying of hypoxemia, and 80% of those dying of MSOF.
Organ dysfunction at time of death was common in all nonsurvivors (Table 1 and Fig. 2 ). Neurologic and cardiovascular failure were more common in patients dying less than 7 days (5) 5 (7) Nonpulmonary sepsis 49 (32) 27 (33) 22 (31) Other 24 (16) 14 (17) 10 (14) Cause of PARDS, n (%) 0.872 after PARDS onset. Respiratory and hepatic failure were more common in patients dying greater than or equal to 7 days.
Detailed Analysis of Time to Death
We examined the association of variables with time to death stratified into smaller epochs (Supplementary Table 2 , Supplemental Digital Content 2, http://links.lww.com/CCM/D929).
As with the primary analysis, subjects dying earlier had higher PRISM scores and were less likely to be immunocompromised (both p < 0.001). There were differences between PARDS etiology and time to death (p = 0.023). Nonpulmonary sepsis was the most common etiology for subjects who died less than or equal to 3 days after PARDS onset, whereas pneumonia was the most common for subjects who died between 4 and less than 7 days. Subjects dying less than or equal to 3 days after PARDS onset died mostly of MSOF or neurologic causes (p < 0.001). Neurologic causes predominated between 4 and less than 7 days. MSOF was the most common cause for subjects dying between 7 and 14 days, whereas hypoxemia and MSOF were the most common for subjects dying after 14 days. Withdrawal of therapy was the most common mode of death, with the prevalence of unsuccessful CPR markedly diminished after 3 days. Neurologic failure was less common in later deaths, particularly greater than 14 days (p < 0.001). Table  3 , Supplemental Digital Content 3, http://links.lww.com/ CCM/D930), they were similar with respect to demographics, severity of illness, and severity of PARDS. CHOP had more immunocompromised subjects (p = 0.003), more pneumonia (p < 0.001), and more inhaled nitric oxide use (p < 0.001), whereas CHLA had more indirect PARDS (p = 0.002). CHOP had more acute neurologic failure, whereas CHLA had more chronic (Supplementary Table 4 , Supplemental Digital Content 4, http://links.lww.com/CCM/D931) (both p < 0.001). Cause of death differed between institutions (p = 0.050), with more neurologic deaths at CHOP, and more MSOF deaths at CHLA.
Comparison Between Institutions When comparing the two institutions (Supplementary
Excluding Brain Death
If excluding subjects with brain death (n = 36; 24% of all deaths), mortality for the PARDS cohort reduced to 15%, and time to death increased to 8 days (3-17 d) after PARDS onset ( Table 2) . Similar to the larger cohort, patients dying less than 7 days had higher PRISM scores. Immunocompromised subjects now comprised 44% of all nonsurvivors and were more prevalent in later deaths (p = 0.009). MSOF was the most prominent cause of both early and late deaths. However, neurologic deaths were more common less than 7 days after PARDS onset, whereas hypoxemia became more common greater than or equal to 7 days. Withdrawal of therapy predominated as mode of death, with a lower prevalence of unsuccessful CPR in later deaths. Organ dysfunction at the time of death remained common.
Excluding Death Due to Neurologic Causes
Acute neurologic failure coincident with PARDS diagnosis was associated with mortality (p < 0.001) (Supplementary Table 4 , Supplemental Digital Content 4, http://links.lww.com/CCM/ D931). Of the 63 nonsurvivors with acute neurologic failure, 52 (82%) ultimately died of a neurologic cause, and 60 (95%) had neurologic dysfunction present at the time of death. If excluding patients with any neurologic cause of death (n = 59; 39% of all deaths), mortality for the PARDS cohort reduced further to 12%, and time to death increased to 10 days (2-19) after PARDS onset ( Table 3) . As before, patients dying less than 7 days had higher PRISM scores. Immunocompromised subjects now constituted 49% of nonsurvivors and were more prevalent among later deaths. MSOF was the most common cause of death, and withdrawal of therapy was the most common mode of death, with decreasing proportion of unsuccessful CPR among later deaths. Organ dysfunction at time of death remained common.
Excluding Subjects on Extracorporeal Support
Because extracorporeal membrane oxygenation (ECMO) can affect the attribution of death due to hypoxemia, we examined subjects placed on ECMO in more detail. Of the 153 nonsurvivors, seven received ECMO. Of these subjects, two died of hypoxemia, three of MSOF, and two of neurologic failure. All ECMO subjects died greater than or equal to 7 days after PARDS onset. Results were unchanged when analyzing the cohort excluding these seven subjects (Supplementary Table  5 , Supplemental Digital Content 5, http://links.lww.com/ CCM/D932). 
DISCUSSION
We describe the epidemiology of the cause of death in children with PARDS, capitalizing on a combined dataset of 798 subjects with PARDS from two academic centers using current management. Children who died less than 7 days after PARDS onset predominantly died from neurologic causes, including brain death. Later deaths were more commonly due to MSOF. Deaths from neurologic causes accounted for 39% of all nonsurvivors. Organ dysfunction was common at time of death, irrespective of cause of death. Refractory hypoxemia accounted for only 20% of PARDS deaths and was more common in those who died greater than or equal to 7 days after PARDS onset. Given the retrospective nature of the study, as well as the subjective aspects of assigning cause of death, we interpret these findings with caution. Our finding that hypoxemia is an uncommon cause of death is consistent with prior studies. In a study of 470 children with acute hypoxemic respiratory failure (203 deaths; 43%) in 1991, hypoxemia as cause of death was attributed to 41 subjects (20%) (6) . Fifty-one subjects (25%) had withdrawal of care, lower than this present study. However, children with poor neurologic prognosis were excluded from this cohort, thus precluding a direct comparison with our study. Furthermore, specific organ failures contributing to MSOF were not described, and etiologies of respiratory failure relied on administrative coding, with less granularity than in the current study. Dahlem et al (21) described 12 PARDS nonsurvivors, seven of whom died from neurologic injury, whereas respiratory failure accounted for two deaths. In a PARDS cohort of 146 patients (38 deaths), MSOF was the cause of death in 40%, whereas respiratory failure was the cause in 26% (22) . Adult studies have reported similar findings (7, 8, 23, 24) , with MSOF accounting for the majority of deaths (over 40%) and respiratory failure accounting for a minority (< 25%).
Neurologic failure was the cause of death in 39% of cases, including 36 subjects with brain death. Neurologic dysfunction was present in nearly half of nonsurvivors, somewhat higher than reported for adults. Stapleton et al (7) reported that neurologic dysfunction was the cause of death in 29% of adult ARDS mortalities. Interventional PARDS trials commonly exclude subjects with limitations of care orders or exceedingly poor neurologic prognosis (13, 14, 25) . This, along with other commonly applied exclusion criteria in clinical trials, likely contributes to why mortality rates extrapolated from observational studies systematically overestimate the observed mortality rates in trials.
The predominance of neurologic and MSOF as causes of death in our study reinforce that PARDS management should be considered in the context of a broader systemic illness. Given the time course in which these deaths occurred in our cohort, it is unlikely that trials focused on PARDS-specific therapies would have any impact on subjects dying less than or equal to (12, 26) . However, this link is more tenuous in PARDS, with no demonstration of an association between either tidal volume (27) or ventilator pressures (28) with mortality in observational studies. Together, these findings highlight the uncertainty of whether interventions predominantly targeting the injured lung will have major impacts on mortality in PARDS.
Reporting mortality as the primary endpoint, or as a component of a composite (such as ventilator-free days), is problematic for interventions primarily postulated to improve lung injury. Mortality in PARDS appears to be primarily related to nonpulmonary organ failures, including neurologic, rather than refractory or persistent hypoxemia. Eligibility criteria for trials excluding subjects with poor neurologic prognosis, refractory shock, or significant comorbidities may mitigate some of these concerns, albeit at the cost of reduced mortality rates and reduced generalizability. Methods exist to deal with studying functional outcomes when some subjects will have unmeasurable outcomes because of death, such as restricting analyses to survivors only or computing a survivor average causal effect (SACE) (29) . In the case of PARDS, the primary outcome of interest could be duration of ventilation. However, survivoronly analyses and SACE require assumptions that may not be plausible (no effect of intervention on mortality) or may be untestable (identification of subjects who would survive irrespective of treatment arm). Clearly, selection of an appropriate outcome for PARDS trials is problematic, potentially requiring further development of statistical methodologies.
Our study has limitations. The retrospective and subjective nature of assigning cause of death could introduce misclassification bias. Additionally, the two-center nature may limit generalizability, although PARDS etiologies and severity were comparable with others (22, (30) (31) (32) . CHOP and CHLA had differences in case mix, with more immunocompromised subjects and acute neurologic failure at CHOP and more indirect PARDS at CHLA. This likely contributed to more neurologic deaths at CHOP and more MSOF at CHLA. These differences may affect the generalizability of our study; however, the combined cohort is potentially more representative of the actual heterogeneity of PARDS. In both institutions, hypoxemia was the least common cause of death. The use of ECMO may alter the cause, mode and timing of death, although exclusion of these subjects did not alter results. Finally, as we could not interview providers or families in real time, the reasons underlying actual withholding or withdrawal of care remain unknown. Thus, whether decisions to limit care were based on specific organ failures, such as neurologic or because of the severity of an underlying comorbidity, such as malignancy, remain speculative.
However, our study has several strengths. This was the first study to describe the epidemiology of death in PARDS using modern ventilator management and PARDS definitions. We also provided a detailed description of failing organs at the time of death. Last, we used two independent investigators at each site and a common data dictionary to minimize misclassification and ensure consistency.
CONCLUSIONS
In PARDS, early deaths are due primarily to neurologic failure, whereas later deaths are more likely to be due to refractory hypoxemia or MSOF. Deaths from neurologic causes accounted for a substantial portion of nonsurvivors. Organ dysfunction is common at time of death, irrespective of cause of death. Hypoxemia accounted for only a minority of deaths. Our study highlights limitations associated with using death as an endpoint in PARDS trials. Therefore, death should be reconsidered as a primary outcome, especially for interventions targeting lung injury. Most subjects appear to die with, but not necessarily from, PARDS.
